Dacogen (decitabine) may be a cancer medication that interferes with the expansion and unfold of cancer cells within the body.
Dacogen is employed to treat myelodysplastic syndromes (certain kinds of blood or bone marrow cancer).
Dacogen may additionally be used for functions ex-directory during this medication guide.
Submit your review
Get emergency medical help if you have any signs of an allergic reaction to Dacogen: hives; difficult breathing; swelling of your face, lips, tongue, or throat.
Call your doctor at once if you have:
fever, chills, body aches, cough, sore throat, flu symptoms;
easy bruising, unusual bleeding (nose, mouth, vagina, or rectum), purple or red pinpoint spots under your skin;
pale skin, feeling light-headed, rapid heart rate, trouble concentrating;
white patches or sores inside your mouth or on your lips; or
stabbing chest pain, wheezing, feeling short of breath, cough with yellow or green mucus;
swelling, pain, tenderness, or redness anywhere on your body; or
electrolyte imbalance (confusion, uneven heart rate, extreme thirst, increased urination, jerking muscle movements, leg discomfort, muscle weakness or limp feeling).
Common Dacogen side effects may include:
headache, dizziness, drowsiness;
nausea, vomiting, stomach pain, diarrhea, constipation;
cough, dry mouth;
joint pain; or
sleep problems (insomnia).
DACOGEN is administered at a dose of 15 mg/m2 by continuous intravenous infusion over 3 hours repeated every 8 hours for 3 days. This cycle should be repeated every 6 weeks. Patients may be premedicated with standard anti-emetic therapy. If hematologic recovery (ANC ≥ 1,000/μL and platelets ≥ 50,000/μL) from a previous DACOGEN treatment cycle requires more than 6 weeks, then the next cycle of DACOGEN therapy should be delayed and dosing temporarily reduced by following this algorithm: